ChemoCentryx Company Description
ChemoCentryx is centering its research on chemokines. The drug developer is working on orally administered drugs that target the body's chemokine system, a molecular network that regulates inflammatory and immune responses. The firm's lead candidate is Traficet-EN, an investigational treatment for Crohn's disease. Its R&D activities for Traficet-EN are part of a broad collaboration with GlaxoSmithKline, under which the druggernaut is providing research funding in return for the right to license Traficet-EN and several other drugs. ChemoCentryx is researching other compounds that may treat autoimmune and inflammatory conditions, including rheumatoid arthritis and inflammatory cardiovascular diseases.
View the Comprehensive Company Description for ChemoCentryx
The Company Description provides a historical perspective of ChemoCentryx's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of ChemoCentryx's evolution in the marketplace.
